Project Grant R43AI134168

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $130,950 to the Regents of the University of Idaho to conduct research focused on understanding the developmental cycle of chlamydial bacteria at the single-cell level. The key products and services to be delivered under this award include: Developing a CRISPR interference (CRISPRi) knockdown screen to assess the...

This three-year, $800,000 Project Grant from the United States Department of Agriculture National Institute of Food and Agriculture (USDA NIFA) supports research under the Agriculture and Food Research Initiative (AFRI) competitive grants program (CFDA 10.310). The University of Wisconsin-Madison will develop DNA-based nanoparticle vaccines (nanovaccines) to improve protection against emerging and transboundary poultry infections such as highly pathogenic avian influenza. Researchers will...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $745,752 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mayo Clinic. The funding supports research to develop an HIV-1 vaccine that can generate strong immune responses at mucosal surfaces, the primary sites of HIV exposure. Key aspects of the project include: Evaluating the ability of a "single-cycle" adenovirus (SC-AD) vaccine platform to amplify antigen production...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $185,513 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Tulane University to develop an enterotoxigenic Escherichia coli (ETEC) multivalent subunit vaccine using outer membrane vesicles. The project aims to establish anti-ETEC immunity in the gastrointestinal tract by testing the hypotheses that antibodies produced from immunization with OMV-adjuvanted ETEC toxoids and colonization factors...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $226,204 to the University of Maryland, Baltimore to investigate the vaginal microbiome and immune response factors that contribute to the spontaneous clearance of Chlamydia trachomatis (CT) infections in women. The key objectives are to: (1) evaluate species- and strain-specific vaginal bacterial growth rates, (2)...

This $300,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research program aims to develop an anti-Candida peptide vaccine. The goal is to create a vaccine that can be used alone or as an adjunct to antifungal drugs to reduce fungal burden and morbidity due to life-threatening disseminated candidiasis, a common bloodstream infection in hospitalized patients. The project will utilize a novel...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $400,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Baylor College of Medicine in Houston, Texas. The funding will support pre-clinical studies to test the prophylactic efficacy of a potential vaccine against extraintestinal pathogenic E. coli (ExPEC), a member of the human microbiome that has become a leading cause of antibiotic-resistant mortality worldwide. The research...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $202,500.00 to support research aimed at understanding the developmental cycle of Chlamydia bacteria at the single-cell level. The award supports two key research aims: 1) Developing a CRISPR-based knockdown screen to assess the role of essential genes in regulating Chlamydia cell types, and 2) Determining the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $288,360 to support the development of a novel vaccine against multi-drug resistant Acinetobacter baumannii (MDR-AB). The 2-year project, awarded to Biological Mimetics, Inc., aims to identify key immunogenic components of MDR-AB, develop a prototype vaccine formulation, and conduct preliminary in vitro and in vivo...

This is a Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855). The $207,225 award supports research to investigate how the bacterium Chlamydia trachomatis manipulates cellular pathways, specifically the PICALM protein, to maintain a "silent" infection within the host cell. The goal is to better understand how Chlamydia utilizes host cell nutrient trafficking to promote its...